MediWound clinical trials we track

Check company identity source

Phase 3 3 trials

Phase 2 1 trial

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-12-28DayNexoBridMediWound Ltd · MDWDFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761192", "applicant_as_listed_by_fda": "MEDIWOUND, LTD", "brand_names": ["NEXOBRID"], "active_ingredients": ["ANACAULASE-BCDB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20221228", "matched_on": "drug name equals FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence (number of patients) of target wound related AEs throughout the trial Description: The endpoint will assess number of patients, in each arm, with reported local (target wound related) AEs Time frame: Throughout the study (week 2- week 15) Measure: Number of patients with Clinically significant changes in vital signs during the Daily Visits Period, Description: Number of patients with Clinically significant changes in vital signs Time frame: Weeks 2-3 (14 days) Measure: Number of patients with Clinically significant changes in clinical laboratory parameters Description: Number of patients with Clinically significant changes in clinical laboratory parameters Time frame: Weeks 2-3 (14 days) Measure: Time to complete wound closure Description: The outcome will assess time to reaching complete wound closure Time frame: Weeks 2-15 Measure: Incidence of complete wound closure Description: The outcome will assess number of patients reaching complete wound closure Time frame: 2-15 weeks. After: Measure: Incidence (number of patients) of systemic and local adverse events (AEs) throughout the trial Description: The endpoint will assess number of patients, in each arm, with reported systemic and local AEs Time frame: Throughout the study (week 2- week 17) Measure: Number of patients with Clinically significant changes in vital signs during the Daily Visits Period, Description: Number of patients with Clinically significant changes in vital signs Time frame: Weeks 2-3 (14 days) Measure: Number of patients with Clinically significant changes in clinical laboratory parameters Description: Number of patients with Clinically significant changes in clinical laboratory parameters Time frame: Weeks 2-3 (14 days) Measure: Time to complete wound closure Description: The outcome will assess time to reaching complete wound closure Time frame: Weeks 2-17 Measure: Incidence of complete wound closure Description: The outcome will assess number of patients reaching complete wound closure Time frame: 2-17 weeks.

Primary completion date changed

Before: 30 Dec 2027. After: 4 Nov 2028.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of complete debridement, clinically (visually) assessed after each application Measure: Incidence of complete wound closure. After: Measure: Incidence of complete debridement, clinically (visually) assessed after each application Measure: Facilitation of wound closure, clinically assessed, as measured by time to complete wound closure.

Check registry source